

Generation of cardiomyocytes from human-induced pluripotent stem cells resembling atrial cells with ability to respond to adrenoceptor agonists

Ahmad, Faizzan S.; Jin, Yongcheng; Grassam-Rowe, Alexander; Zhou, Yafei; Yuan, Meng; Fan, Xuehui; Zhou, Rui; Mu-u-min, Razik; O'Shea, Christopher; Ibrahim, Ayman M.; Hyder, Wajiha; Aguib, Yasmine; Yacoub, Magdi; Pavlovic, Davor; Zhang, Yanmin; Tan, Xiaoqiu; Lei, Ming; Terrar, Derek A.

DOI:

[10.1098/rstb.2022.0312](https://doi.org/10.1098/rstb.2022.0312)

License:

Creative Commons: Attribution (CC BY)

Document Version

Publisher's PDF, also known as Version of record

Citation for published version (Harvard):

Ahmad, FS, Jin, Y, Grassam-Rowe, A, Zhou, Y, Yuan, M, Fan, X, Zhou, R, Mu-u-min, R, O'Shea, C, Ibrahim, AM, Hyder, W, Aguib, Y, Yacoub, M, Pavlovic, D, Zhang, Y, Tan, X, Lei, M & Terrar, DA 2023, 'Generation of cardiomyocytes from human-induced pluripotent stem cells resembling atrial cells with ability to respond to adrenoceptor agonists', *Royal Society of London. Proceedings B. Biological Sciences*, vol. 378, no. 1879, 20220312. <https://doi.org/10.1098/rstb.2022.0312>

[Link to publication on Research at Birmingham portal](#)

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Download date: 29. May. 2023

Research



Cite this article: Ahmad FS *et al.* 2023
Generation of cardiomyocytes from human-
induced pluripotent stem cells resembling
atrial cells with ability to respond to
adrenoceptor agonists. *Phil. Trans. R. Soc. B*
378: 20220312.
<https://doi.org/10.1098/rstb.2022.0312>

Received: 17 September 2022
Accepted: 7 December 2022

One contribution of 23 to a theme issue ‘The
heartbeat: its molecular basis and physiological
mechanisms’.

Subject Areas:

physiology, biochemistry, cellular biology,
molecular biology

Keywords:

iPSCs, iPSC-derived atrial cardiomyocytes,
Gremlin 2, retinoic acid, adrenergic receptor,
calcium

Author for correspondence:

Derek A. Terrar
e-mail: derek.terrar@pharm.ox.ac.uk

[†]Joint first authors.
[‡]Senior author.

Generation of cardiomyocytes from human-induced pluripotent stem cells resembling atrial cells with ability to respond to adrenoceptor agonists

Faizzan S. Ahmad^{1,2,†}, Yongcheng Jin^{1,†}, Alexander Grassam-Rowe^{1,†},
Yafei Zhou^{3,4}, Meng Yuan^{1,5}, Xuehui Fan³, Rui Zhou³, Razik Mu-u-min¹,
Christopher O’Shea⁶, Ayman M. Ibrahim^{7,8}, Wajiha Hyder¹, Yasmine Aguib^{7,9},
Magdi Yacoub^{7,9}, Davor Pavlovic⁶, Yanmin Zhang⁴, Xiaoqiu Tan^{3,‡}, Ming Lei^{1,‡}
and Derek A. Terrar^{1,‡}

- ¹Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, UK
²Cure8bio, Inc, 395 Fulton Street, Westbury, NY 11590, USA
³Key Laboratory of Medical Electrophysiology of the Ministry of Education and Institute of Cardiovascular Research, Southwest Medical University, Luzhou 6400, People’s Republic of China
⁴Shaanxi Institute for Pediatric Diseases, Department of Cardiology, Xi’an Children’s Hospital, Xi’an 710003, People’s Republic of China
⁵Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA
⁶Institute of Cardiovascular Sciences, College of Medicine and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK
⁷Aswan Heart Centre, Aswan 1242770, Egypt
⁸Department of Zoology, Faculty of Science, Cairo University, Cairo 12613, Egypt
⁹National Heart and Lung Institute, Heart Science Centre, Imperial College London, Middlesex SW3 6LY, UK
- ID** YZ, 0000-0001-7580-4693; XT, 0000-0003-0062-6209; ML, 0000-0002-0928-341X;
DAT, 0000-0001-9408-6594

Atrial fibrillation (AF) is the most common chronic arrhythmia presenting a heavy disease burden. We report a new approach for generating cardiomyocytes (CMs) resembling atrial cells from human-induced pluripotent stem cells (hiPSCs) using a combination of Gremlin 2 and retinoic acid treatment. More than 40% of myocytes showed rod-shaped morphology, expression of CM proteins (including ryanodine receptor 2, α -actinin-2 and F-actin) and striated appearance, all of which were broadly similar to the characteristics of adult atrial myocytes (AMs). Isolated myocytes were electrically quiescent until stimulated to fire action potentials with an AM profile and an amplitude of approximately 100 mV, arising from a resting potential of approximately -70 mV. Single-cell RNA sequence analysis showed a high level of expression of several atrial-specific transcripts including *NPPA*, *MYL7*, *HOXA3*, *SLN*, *KCNJ4*, *KCNJ5* and *KCNA5*. Amplitudes of calcium transients recorded from spontaneously beating cultures were increased by the stimulation of α -adrenoceptors (activated by phenylephrine and blocked by prazosin) or β -adrenoceptors (activated by isoproterenol and blocked by CGP20712A). Our new approach provides human AMs with mature characteristics from hiPSCs which will facilitate drug discovery by enabling the study of human atrial cell signalling pathways and AF.

This article is part of the theme issue ‘The heartbeat: its molecular basis and physiological mechanisms’.

1. Introduction

Atrial fibrillation (AF) is the most frequently encountered arrhythmia in clinical practice and represents a significant disease burden worldwide, with a high

prevalence and ability to cause morbidity and mortality in the population, particularly in the elderly [1]. Current treatments of AF have major limitations including limited efficacy and significant adverse effect liability. These limitations have inspired substantial efforts concerning mechanistic research and innovative approaches for the development of new therapies, such as tailoring treatment to the underlying pathophysiology of AF [2]. For achieving such a goal, suitable model systems replicating the adult human atrial cardiomyocyte (CM) phenotype are required.

In recent years, human-induced pluripotent stem cells (iPSCs) have emerged as an alternative *in vitro* model system to the use of animals for investigation of human disease mechanisms and development of new medications. Numerous disease-specific iPSC lines have been produced for modelling congenital cardiac arrhythmia syndromes, including heritable AF [3–5]. Although iPSCs hold great promise for heart disease research and treatment, there are obvious obstacles to be overcome. For instance, cardiogenic differentiation of iPSCs by existing protocols often produces a heterogeneous mixture of CMs of different subtypes, primarily ventricular CMs. More importantly, a major problem is the maturation of CMs from hiPSCs, since the resultant cells frequently display developmentally immature characteristics which are analogous to fetal CMs [6,7]. The immaturity of CMs derived from hiPSCs makes them less suitable models for studying the most common heart diseases, that typically occur in adulthood, and also diminishes the suitability of such models for drug screening. Over the past few years, great efforts have been made by a number of groups in developing new approaches in the generation of human embryonic stem cell (hESC)- or hiPSC-derived atrial CMs [8–15]. A particular molecule that has attracted attention and is being used for generating hESC- or hiPSC-derived atrial CMs is retinoic acid (RA), a metabolite of vitamin A1, that mediates the functions of vitamin A1 required for growth and development. An earlier elegant study reported by Keller's group [16] determined RA and WNT signalling as key regulators of human stem cell development. Their study thus provides molecular insights that aid in developing strategies for the generation of atrial CMs from PSCs. Additionally, other groups have inspected Gremlin2 as a pro-atrial differentiation factor and reported promising results [17]. Gremlin 2 is a signalling molecule involved in cardiac development and atrial-specific differentiation as cardiac progenitor cells migrate [17–19]. These studies have thus prompted the efforts in developing protocols for generating hESC- or hiPSC-derived atrial CMs. Atrial CMs derived by these different approaches showed enhanced expression of atrium-specific genes and reduced expression of ventricle-specific genes, but, these cells still show important differences from mature atrial myocytes (AMs; table 1), particularly in their electrophysiological characteristics: for example, such cells frequently lack a stable resting potential, or when there is a stable resting potential the level is substantially more positive than that observed in the adult phenotype.

Here we report a new approach that is able to generate hiPSC-derived atrial myocytes (hiPSC-AMs) showing mature characteristics, using a newly developed differentiation protocol involving a treatment regimen combining RA and Gremlin 2. With our RA- and Gremlin 2-based differentiation protocol, we observed a high proportion of elongated cells, some of which showed a remarkable adult AM-like morphology. Action potentials (APs) with an

atrial-type morphology were recorded following electrical stimulation of quiescent cells, and the cells also showed a remarkable response to adrenergic stimulation that has not been shown in previous reports in RA-guided differentiation protocols, to the authors' knowledge [11–13]. CMs differentiated from hiPSCs using our new RA/Gremlin 2 protocol also showed an atrial-like transcriptomic profile with high level of expression of several atrial-specific transcripts including *NPPA* (natriuretic peptide A), *MYL7* (myosin light chain 2, atrial isoform), *KCNJ5* (Kir3.4 subunit for conducting $I_{K_{ACH}}$) and *KCNA5* ($K_{V1.5}$ for conducting $I_{K_{ur}}$) as compared with a control group treated with a standard conventional commercial CM differentiation protocol. Our new method therefore provides an effective approach for differentiating human AMs with mature characteristics from iPSCs. These cells are likely to be very useful for studying the presence and function of components of cell signalling pathways in human AMs and will probably provide a valuable model for modelling AF disease and drug discovery.

2. Results

(a) Morphological and immunocytochemistry characterization reveals a more mature atrial-like structure in Gremlin 2/retinoic acid-treated cells

Previous studies showed that the *in vitro* specification of CM subtypes is initiated after the induction of mesoderm and before the terminal differentiation of cardiac progenitor cells [9,12]. Therefore, we speculated that a combination of the Gremlin 2 and RA treatment within this time window might be more effective for directing differentiation of iPSCs towards a cardiac atrial phenotype. Thus, we developed our atrial-specific differentiation protocol as shown by the schematic diagram in figure 1a, with the detailed protocol described in Appendix S1. Briefly, in this protocol, Gremlin 2 was added prior to RA. We then characterized the functional and structural properties of the resulting derived cells, as described below. The experiments were conducted from two independent iPSC lines and multiple batches of cells.

The cells prepared from the control group (commercial PSC Cardiac Differentiation Kit Gibco™ Technologies, cat. no. A2921201) and cells treated with Gremlin 2/RA (defined as the experimental group) were characterized by immunocytochemistry to determine their morphology and expression of CM-specific proteins, particularly those expressed specifically in AMs. The cytoskeletal protein ACTN2 (α -actinin 2) and TNNT2 (cardiac troponin C2) were in both control and experimental (day 20) cell cultures (figure 1b). However, labelling for atrial-specific NPPA (natriuretic peptide A) and COUP-TFII (also known as nuclear family receptor 2, group F, member 2) was clearly evident in the experimental group but not control group (figure 1b). Further immunohistochemistry was carried out in individual cells following single-cell isolation from cell cultures (see Material and Methods). We observed the same general expression of ACTN2 and TNNT2 in both experimental and control isolated CM groups, but only NPPA and COUP-TFII expression in the experimental Gremlin 2/RA-treated group (figure 1c).

The morphology of some of iPSC-derived AMs shown in figure 1c was remarkably similar to that of adult AMs observed in human and animal hearts [15,35]. An elongated

protocol	structure	electrophysiology	autonomic pharmacology	molecular markers
native human atria				
Benardeau, Amos, Dobrev, Grandi, Pandit, Wang, Jeevaratnam, Bosch, Bolger, Cui, Li, [20–29]	CMs demonstrate an elongated rod-like morphology, with coordinated and striated myofibrillar ultrastructure. Single nucleus [20]	CMs demonstrate a more triangular-like AP morphology that is also shorter than the ventricular APD. APD ₉₀ approximately 150–500 ms, APD ₅₀ approximately 8–150ms, APD ₃₀ approximately 4–24 ms. CMs have a more depolarized resting membrane potential (approx. –74 mV) than their ventricular cells (approx. –81 mV) [21–25,30]	respond to adrenergic stimuli with positive inotropic and chronotropic effects, which are opposed by cholinergic stimuli. Respond to a range of neurohormonal stimuli at nM concentrations. (e.g. 1 nM ISO). Respond to parasympathetic stimulation: activation of I _{KACH} in response to 1 μM ACh (–20 pA/pF at –90 mV) [26,27]	differ at the transcriptomic level from both the ventricles and more immature atria. A ‘master’ transcription factor (NR2F2) activates and maintains the atrial transcription program which differs both from the ventricular programme, and from that of the immature atrium across a range of structural and functional gene sets [28,29,31]
RA				
Devalla [8]	beating embryoid bodies from hESC, with mostly roundish cells; few with clear organized myofilaments	AP with pronounced phase 1 repolarization. Reduced AP plateau and APA _{max} height compared to control. Shorter APD ₂₀ (20.8 ± 3.7 ms), of ventricular APD ₅₀ (44 ± 10 ms), and APD ₉₀ (145 ± 21 ms) compared to control. No difference in RMP (ca –72 mV) from control	10 μM CCh induced a CCh-sensitive current (I _{KACH}) with –2 pA/pF at –120 mV	downregulation of ventricular markers such as IRX4, MYL2 and HEY2 with concomitant upregulation of atrial markers such as NPPA, SLN, PITX2, NR2F2 and KCNA5. Demonstrated a COUP-TFII-dependent atrial transcriptome. Increased expression of atrial-enriched potassium channel subunit-encoding genes
Li [31]	formed cell sheets and EHT with organized sarcomeric structure	fired triangular-like APs, with a mean diastolic potential of –77.4 ± 1.4 mV, with a shorter APD than the ventricular control, but the same as the sinoatrial control. However, atrial iPSC had a higher maximal upstroke velocity than the sinoatrial group	responded to noradrenaline (100 nM) to reduce cycle length as single cells, and dose-dependent increase in beating rate of atrial EHT from hiPSC. 1 μM CCh increased single-cell iPSC-AM spontaneous beating cycle length, this occurred in a dose-dependent manner in atrial engineered heart tissue (EHT)	increased expression of <i>NPPA</i> , <i>NR2F2</i> and <i>KCNJ3</i> compared to ventricular controls, but only <i>NPPA</i> was higher compared to the sinoatrial controls
Cyganek [12]	formed cell sheets with good alignment of myofilaments in some areas	fired triangular-like APs (APD ₂₀ /APD ₈₀ of 0.12 ± 0.01), with an APD ₅₀ of 167 ± 5 ms. Shorter more triangular calcium transients than control	positive inotropic response to 1 μM ISO. Negative inotropic response to 10 μM CCh	comprehensive increase in atrial markers such as <i>NPPA</i> , <i>NR2F2</i> , <i>KCNJ3</i> , <i>HOXA3</i> , <i>KCNA5</i> , along with a decrease in ventricular markers such as <i>MYL2</i> , <i>IRX4</i> , <i>MYH7</i> , <i>LPL</i> and <i>HEY2</i> . Confirmed the proteomic signal of atrial markers

(Continued.)

Table 1. (Continued.)

protocol	structure	electrophysiology	autonomic pharmacology	molecular markers
Argenziano [11]	fibre-like tissue structures form from cell sheets of hiPSC-AMs	fired triangular-like APs (APD ₉₀ /APD ₅₀ 1.3 ± 0.01), from a RMP of -45.2 ± 2.7 mV, with an APD ₅₀ of 57.5 ± 2.7 ms, an APD ₉₀ 89 ± 4.5 ms	10 μM CCh activated I _{KACH} of -2.5 pA/pF at -120 mV. 100 μM adenosine also activated an I _{KACH} current of -1 pA/pF at -120 mV	downregulated <i>MYH7</i> , <i>MYL2</i> and <i>MYL2</i> at the protein level as <i>MLC2v</i> but upregulated <i>KCNJ3</i> , and <i>KCNA5</i> , <i>NR2F2</i> , <i>GJA5</i> and <i>KCNA5</i> , <i>COUP-TFII</i> , <i>Ca_v3.1</i> at the protein-level
Laksman [10]	elongated cells in sheets with organized sarcomeric striations along the long axis	fired APs with a pronounced notch and plateau. APs arose from a RMP of -56 ± 2 mV, with an APD ₃₀ of 37 ± 11 ms and APD ₉₀ of 247 ± 37 ms. Atrial sheets can produce organized rotors	not shown	upregulated <i>NPPA</i> , <i>KCNJ3</i> and <i>GJA5</i> . downregulated <i>MYL2</i> and <i>IRX4</i>
Pei [32]	formed beating cell sheets, with striated sarcomeric ultrastructure	fired triangular APs, with an APD ₉₀ of ca 75 ms, from a mean diastolic potential of ca -55 mV	not shown	downregulated <i>IRX4</i> , and upregulated <i>NR2F2</i> compared to control. Atrial cell sheets were also <i>MLC2v</i> negative
Goldfracht [33]	organized into ring-shaped EHT	fired triangular APs, with an APD ₉₀ 205 ± 9 ms, APD ₅₀ 147 ± 10 ms, and APD ₃₀ 115 ± 9 ms from a RMP of 63 ± 2 mV	10 μM ISO increased force of contraction by ca 70%. Responded to CCh in a dose-dependent manner (2.5, 5, 10 μM), with a reduction in APD ₉₀ from 297 ± 16 ms at 0 μM, to 233 ± 17 ms at 10 μM CCh	lower <i>MLC2v</i> expression than ventricular control. Atrial EHT upregulated <i>KCNA5</i> , <i>KCNJ3</i> , <i>NPPA</i> , <i>MYL7</i> , <i>NR2F2</i> and downregulated <i>MYL2</i> , <i>MYH7</i> , <i>HEY2</i> . Atrial EHT also had higher <i>SLN</i> and <i>CX40</i> expression
GREM2				
Tanwar [19]	not shown	CGR8 mESCs-CMs fired triangular APs, with an APD ₉₀ of approximately 40 ms versus control of approximately 70 ms which have a pronounced notch and dome morphology	not shown	CGR8 mESCs-CMs had higher expression of <i>Nkx2.5</i> , and <i>Myh6</i> . GREM2 treatment also increased expression of <i>Tnnt2</i> , <i>Gata4</i> , <i>Myl7</i> , <i>Gja5</i> , <i>Kcnj5</i> and <i>Hey1</i> compared to control. Whereas, GREM2 treatment decreased expression of more ventricular transcripts such as <i>Myl2</i> , <i>Gja1</i> and <i>Kcnq1</i>
Bylund [34]	increased % contracting cells, and increased number of CPCs	not shown	not shown	increases expression of <i>NKX2.5</i> , <i>MYH6</i> , <i>TNNT2</i> and <i>MYL7</i> . GREM2 effect was JNK-dependent

(Continued.)

Table 1. (Continued.)

protocol	structure	electrophysiology	autonomic pharmacology	molecular markers
GREM2 and RA				
Ahmad (this paper)	elongated rod-like morphology in some, with organized striated sarcomeres. iPSC-AMs form cTnT ⁺ beating cell sheets	fired triangular-like APs, although with some plateau, from a baseline RMP of -67 ± 6 mV. APs have an APD ₉₀ 215 ± 30 and APD ₅₀ 130 ± 30 (APD ₉₀ /APD ₅₀ <i>ca</i> 1.7)	responded to α - (10 μ M PE) and β -adrenergic (100 nM ISO) stimuli, sensitive respectively to blockade by prazosin (1 μ M α -antagonist) and CGP20712A (600 nM, β_1 -selective antagonist). α - and β -stimuli both increased calcium transient amplitude. Demonstrated I _{KACH} current <i>ca</i> -30 pA/pF at -110 mV with 1 μ M ACh	increased COUP-TFII and NPPA expression relative to control. At the mRNA level, expressed a range of cardiac TFs, including NR2F2, coupled to downstream-effector modules such as GATA4, GATA5, GATA6, HEY1, SFRP5 and MEF2D. higher expression of a range of atrial-associated transcripts compared to control (e.g. NPPA, MYL7, KCNA5). Robust expression of contractile and calcium-handling proteins

rod-like morphology resembling the adult phenotype was observed across much of our experimental group (figure 1c), which was comparable to that reported in human mature AMs [15,35]. Furthermore, our Gremlin2/RA experimental group also showed a well-organized striated sarcomeric pattern with sarcomere spacing slightly less than 2 mm (figure 1c), as observed in adult CMs [15,35]. The percentage of CMs in the experimental group that were positive for the atrial-specific COUP-TFII/NPPA was 77% from approximately 1000 counted cells, in contrast with less than 10% in the control group (figure 1d); thus supporting that our hiPSC-AM differentiation protocol established robust protein expression for selected major atrial transcription factors and associated atrial markers.

(b) Transcriptional characterization identifies a more robust atrial transcriptional program in Gremlin 2/retinoic acid-treated cells

To gain insights into the molecular signature of the iPSC-derived atrial CMs from the experimental group and their differences from the control iPSC-derived CMs, we performed single-cell RNA-sequencing (scRNASeq) on over 300 cells from each control and treatment group. We first sought to characterize the percentage of atrial CMs detected in our sample across an orthogonal gene set to NR2F2 [36] as in figure 1. The experimental group showed a high expression of four markers that are characteristic of atrial CMs: HEY1, MYL7, HOXA3 and SLN (figure 2a). The experimental group was composed 71% of these atrial CMs, whereas the control group only 16% (figure 2a). Thus, our transcriptomic calculation of atrial CM abundance supports our earlier results with proteomic identification and calculation.

To better understand the differences between our experimental and control groups, we identified the differentially

expressed genes between the groups (figure 2b). Gene expression consistent with atrial CMs (including MLY7, HEY1, HOXA11, SLN, MYH6, KCNH2, GATA4 and NPPA) was upregulated in the experimental group, while iPSC-derived CMs from the control group showed higher expression of certain ventricular CM-specific genes (including GJA1 coding for CX43, LPL coding for lipoprotein lipase and SCUBE3 coding for signal peptide CUB-EG-containing protein 3) (figure 2b). Notably, we found that genes encoding potassium channels K_V1.5 (KCNA5) and K_V11.1 (KCNH2) displayed significantly higher expression in CMs from the experimental group compared with CMs from the control group. These potassium channels contribute significantly to the shape and function of APs in human AMs. KCNA5 encodes a subunit of a delayed rectifier potassium channel K_V1.5, underlying the ultra-rapidly activating delayed rectifier K⁺ current I_{Kur} found in human atrial CMs [37].

We next sought to further investigate the differentially expressed genes between the two groups beyond the level of isolated genes. We used gene ontology (GO) analysis to ascertain if the differentially expressed genes had any enrichment for shared gene function annotations. We identified the top 10 most enriched GO terms, which suggest a difference between groups across a range of significantly enriched functional annotations, relating to organization of the extracellular matrix, replication and cardiac muscle tissue development (figure 2c). Thus, our analysis suggests that our experimental group expresses a diversity of genes of known atrial significance, and that this expression is not just across a few genes but across sets of these genes.

We then sought to identify the expression of specific genes of interest across a range of important modules associated with atrial differentiation and maturation: atrial transcriptional programme markers, potassium channels, contractility and calcium handling. We observe that the experimental group had higher expression of key atrial




Figure 1. Gremlin2/RA-mediated differentiation of iPSCs into atrial cardiomyocytes (CMs). (a) Schematic of the atrial-specific differentiation protocols. Human iPSCs were dissociated into single CMs for the differentiation experiments. mTesR1 is a defined tissue culture medium from Stemcell Technologies. Cardiac differentiation medium A (CDM A) including CHIR99021 and cardiac differentiation medium B (CDM B) were applied to both groups. From day 4, all CMs were maintained in CMM. In the Experimental group, Gremlin 2 (1 mg ml^{-1}) was added at day 4, and of RA (1.0 mM) was added with Gremlin 2 still present at day 6, while the control group of cells was differentiated without the addition of Gremlin 2 and RA. (b) Functional analysis was performed after day 20 when both cell populations of hiPSC-derived CMs showed the expression of the CM-specific cytoskeleton markers α -actinin 2 (ACTN2) and TNNT2 (cardiac troponin C2), while the expression of the atrial CM-specific markers COUP-TFII and NPPA was restricted to the experimental group. (c) Immunofluorescence labelling of the cytoskeleton markers α -actinin 2 and F-actin for cells in the experimental group demonstrating an elongated morphology with striations. (d) The percentage of COUP-TFII positive CMs was 77% in the experimental Gremlin2/RA-treated group. A total of approximately 1000 DAPI-stained cell nuclear were identified in both treated and control groups, and then they were overlapped with COUP-TFII positive nuclear to calculate the percentage of COUP-TFII positive cells. A Chi-square test was applied, $n = 1000$, $p < 0.001$.

markers such as *NR2F2*, *SLN*, *HEY1*, *HOXA3* and *NPPA* (figure 2d); whereas the control group expressed more ventricular markers, such as *IRX5* that is an important driver in

development of the ventricular transcriptional programme [38] (figure 2d). However, we note that the experimental group also had increased expression across other genes




Figure 2. (Caption overlaid.)

pertinent for the specification of chamber-specific lineages (figure 2*d*).

Potassium currents are particularly important for defining the specific AP morphology and electrophysiological behaviour of atrial CMs [39]. We saw an increased expression of several potassium channel-encoding genes (figure 2*e*(i)). Of particular interest is the higher expression of *KCNJ2*, that

encodes $K_{ir2.1}$, which gives rise to the inwardly rectifying I_{K1} current—a current that demarks more mature atrial CMs [40].

Appropriate contractile effort in CMs derives from mature molecular organization of actomyosin filaments into sarcomeres connected through to the cell surface and extracellular matrix. Our experimental group has much higher expression of atrial-

Figure 2. (*Overleaf.*) Single-cell transcriptomic profile. (a) Plot showing the percentage of cardiomyocytes (CMs) expressing atrial-specific markers HEY1, MYL7, HOXA3 and SLN in the experimental and control groups. (b) Differential gene expression analysis showed many upregulated atrial-specific gene in experimental group with selected markers indicated. (c) Gene ontology (GO) plot showing the top 10 most enriched GO terms in the genes differentially expressed between the control and experimental group. Coloured by Bonferroni–Hochberg-adjusted p -value. Gene count along the x -axis marks the number of genes enriched within each GO term. (d) Heatmap plot showing the expression of cardiogenic and chamber-specific markers. Cells are coloured by relative expression. The annotation on the left indicates the specific fold change in expression from the control group to the experimental group. (e) (i) Heatmap plot showing the expression of genes coding for potassium handling proteins. Cells are coloured by relative expression. The annotation on the left indicates the specific fold change in expression from the control group to the experimental group. The associated currents for each channel subunit are annotated on the left. (ii) Heatmap plot showing the expression of genes coding for contractility-associated proteins. Cells are coloured by relative expression. The annotation on the left indicates the specific fold change in expression from the control group to the experimental group. (iii) Heatmap plot showing the expression of genes coding for calcium-handling proteins. Cells are coloured by relative expression. The annotation on the left indicates the specific fold change in expression from the control group to the experimental group. The associated currents/roles for each protein subunit are annotated on the left. (f) Violin plots of individual expression of genes coding for atrial proteins (*MYL7*, *NPPA*, *KCNJ3*, *GJA5*) at day 20. (g) Time-lapse quantitative reverse transcription-polymerase chain reaction (qRT-PCR) gene analysis of *NPPA* over a 20-day time course, and qRT-PCR analysis of expression on day 15 of genes coding for proteins that are specific for either of atrial (*MYL7*, *KCNJ2*, *PITX2*, *KCNA5*) or ventricular (*IRX4*, *MYL2*) CMs. Values shown are relative to housekeeping gene coding for *HPRT*. $n = 5$ batches of cells. Bars show s.d. of mean. # indicates $p < 0.001$, and ** indicates $p < 0.05$.

specific contractile genes, such as *MYH6*, *MYL7* and *MYL4*; more general sarcomeric genes, such as *TTN*, *TNNT2*, *MYOM1* and *MYBPC3*; genes that integrate the sarcomeric contraction with the rest of the cytoskeleton and sarcolemma, such as *DMD* and *DES*; and hypertrophy-associated genes, such as *DCN* and *SMPX* (figure 2*e*(ii)).

Normal calcium handling is of major importance for normal CM function and the use of hiPSC-derived atrial CMs for studying atrial disease. Our data reveals that our experimental group has higher expression of genes coding for proteins associated with both sarcoplasmic reticulum (SR)-associated calcium handling and membrane calcium handling (figure 2*e*(iii)). In particular, our experimental group has higher expression of genes coding for the major SR calcium-handling proteins *RYR2*, *TRDN* and *FKBP1B* alongside high expression of the gene coding for *ATP2A2* (figure 2*e*(iii)): whereas the control group had higher expression genes coding for the pre-dominantly non-cardiac *RYR3* isoform [41]. Additionally, our experimental group has higher expression of the gene coding for *SLC8A1*, which is a key protein for CM ionic homeostasis, and higher expression of genes coding for T-type calcium channel proteins, *CACNA1H* and *CACNA1G* which contribute to atrial-specific electrophysiology, with *CACNA1H* being particularly implicated postnatally [42,43].

We also demonstrate that our experimental group has higher expression of a range of metabolic genes, including the important transcription factor *PPARGC1A*, which drives mitochondrial biogenesis and oxidative metabolism [44]. Furthermore, we also observe differences in genes coding for adrenergic signalling-associated proteins between our Gremlin 2/RA-treated experimental group and the control, particularly across regulatory cAMP/cGMP phosphodiesterase proteins. Finally, we observe robust expression of *GJA1*, and *ATP1A1* across our experimental and control group, and slightly increased *GJA5* expression in our experimental group—suggesting that our experimental group retains expression of expected genes coding for sodium conductance-related proteins, while moving towards an atrial phenotype.

We sought to focus on several key genes to further validate these findings. First, we show the expression distribution spread, using our scRNASeq results, showing increased expression across the population of our experimental group for *MYL7*, *KCNJ3*, *NPPA* and *GJA5* (figure 2*f*). Then we sought to validate these findings using an orthogonal

method: quantitative polymerase chain reaction (qPCR). *NPPA* expression was examined over the first 20 days, while expression for the other genes of interest was measured on day 15 (figure 2*h*). In agreement with our scRNASeq results, qPCR showed significantly higher expression of the atrial-specific genes *NPPA*, *MYL7*, and preferentially expressed atrial genes such as *KCNJ2*, *KCNA5* and *PITX2* in cells from the Gremlin 2/RA treatment group. However, the control group had much higher expression of ventricular-associated genes such as *MYL2* and the transcription factor *IRX4* [45]. Of particular note, the expression of *MYL7*, the gene encoding myosin light chain 2 atrial isoform (*MLC2A*), is 20-fold higher in cells from the experimental Gremlin 2/RA treatment group than in hiPSC-derived CMs differentiated by the control commercial protocol, which is consistent with abundance of *MYL7* in adult atrial CMs [36]. Therefore, we validated the distinct atrial-like transcriptomic phenotype observed in our Gremlin 2/RA-treated experimental group.

(c) Electrophysiological characterization reveals Gremlin 2/retinoic acid treatment produces a more atrial-like electrophysiological behaviour

The electrophysiological properties of atrial CMs are distinct from those of ventricular CMs. The resting membrane potential for human AMs has been reported around -74 mV, which is more depolarized than in ventricular cells ($ca -81$ mV) [30]. Additionally, APs in atrial cells have a smaller upstroke amplitude with the absence of a prominent plateau phase during the repolarization process [30]. Observations in animal models reproduce these findings that atrial cells have smaller amplitude and shorter duration APs [46]. Electrophysiological characteristics were investigated in our Gremlin 2/RA-treated hiPSC-derived atrial CMs on day 20–21 of differentiation and compared with the observations in adult human atrial and ventricular myocytes described above. The cultures were dispersed into individual myocytes as described for the immunohistochemistry experiments reported (see Material and Methods). AP recordings of the experimental group cells were obtained by patch clamp under the whole-cell configuration. Patch clamp results revealed an atrial-like AP in the experimental group cells as shown in figure 3*a*. Spontaneous activity was also detected in a small subset of cells (figure 3*a*(iii,iv)) while most others

were quiescent until stimulated to fire APs by application of current stimuli through the patch electrode (figure 3a(i,ii)). Particularly, atrial characteristics were the absence of a prolonged plateau and relatively rapid repolarization. The action potential duration (APD) at 90 and 50% repolarization (APD₉₀, APD₅₀) observed in seven experimental cells were 215 ± 30 ms and 130 ± 30 ms (*n* = 7). The average resting membrane potential of examined hiPSC-derived atrial CMs was -67 ± 6 mV (*n* = 7), which is close to that obtained from human atrial CMs -74 mV as previously reported [30]. In addition, action potential amplitude (APA) was 99 ± 3 mV recorded in our hiPSC-derived atrial CMs. This is comparable to that of human adult atrial CMs which is 89 ± 11 mV [30]. The observations on resting potential, APA and APD are shown as bar graphs in figure 3b.

By contrast, the morphology and characteristics of the APs recorded from our control commercially treated cells show ventricular-like features as shown in figure 3c. For example, the average resting membrane potential of commercially derived hiPSC-CMs was -68 ± 2 mV (*n* = 5). The APD₉₀ and APD₅₀ observed in these same control group cells were 297 ± 13 ms and 226 ± 20 ms (*n* = 5). In addition, APA was 111 ± 6 mV recorded in these control iPSC-CMs (*n* = 5).

To further examine the characteristics of the Gremlin 2/RA-treated hiPSC-derived atrial CMs: we assayed their response to acetylcholine (ACh) through the key atrial ACh-activated inwardly rectifying potassium current I_{KACH} [47,48]. Figure 3d shows currents induced by exposure to ACh under voltage clamp conditions. The panel on the right in figure 3d shows a plot of current against voltage. The ACh-induced current showed the expected inward rectification behaviour with a steeper slope of current against voltage for inward currents at more negative potentials as compared to the flatter curve for outward currents at depolarized membrane potentials. By contrast, cells from the control group of hiPSC-CMs, with a more ventricular phenotype, showed little or no current in response to ACh (figure 3d). The observations showing I_{KACH} in hiPSC-derived atrial CMs provide a functional counterpart to the observations in figure 2 showing robust expression of *KCNJ3* that encodes the protein GIRK1, that in turn comprises the channel which carries I_{KACH} [48].

In summary, the characteristics of APs recorded from our Gremlin 2/RA-treated hiPSC-derived atrial CMs were broadly similar to those reported for adult human atrial CMs and demonstrated differences from the control group consistent with the difference from more ventricular cells.

(d) α - and β -adrenergic stimulation increased the calcium transient amplitude in our Gremlin 2/retinoic acid-treated human-induced pluripotent stem cell-derived atrial cardiomyocytes

We also tested whether our Gremlin 2/RA-treated hiPSC-derived atrial CMs responded to adrenoceptor stimulation. The presence of a functional α_1 -adrenoceptor signalling pathway was first tested by exposure of hiPSC-derived atrial CMs to phenylephrine (PE) (an α -adrenoceptor agonist), which in adult atrial CMs increases Ca²⁺ currents [49]. hiPSC-derived atrial CMs from days 25 to 30 were used to assess the effect of PE on Ca²⁺ transient amplitude. Figure 4a shows that 10 μ M PE increased Ca²⁺ transient amplitude by

28 ± 10% as measured from the fluo-4 fluorescence (*p* < 0.05, *n* = 5 batches of cells) but had no effect on the Ca²⁺ transient rise time or decay time. The involvement of α -adrenoceptors was further evaluated by 1 μ M prazosin, a selective α_1 -adrenoceptor antagonist, which by itself had no effect on the amplitude of Ca²⁺ transients (*p* < 0.05, *n* = 4 batches of cells, data not shown). Figure 4c shows that in the presence of 1 μ M prazosin, 10 μ M PE did not cause any significant change in the amplitude of Ca²⁺ transients (*p* > 0.05, *n* = 4 batches of cells), consistent with the blockade of α -adrenoceptors by prazosin and the consequent suppression of the action of the agonist PE under these conditions (*p* < 0.05, *n* = 4 batches of cells).

α - and β -adrenergic receptors are highly expressed in human heart, with β -receptors more abundant than α -receptors. β -receptor stimulation leads to increased synthesis of cAMP and activation of protein kinase A which subsequently phosphorylates L-type Ca²⁺ channels and phospholamban, leading to increased Ca²⁺ influx and Ca²⁺ uptake into the SR [50]. As shown in figure 4b, 10 min of 100 nM isoprenaline (ISO) (a non-selective β agonist) treatment led to an increase of 26 ± 5% in the calcium transient amplitude (*p* < 0.05, *n* = 4 batches of cells). As shown in figure 4d, the involvement of β_1 -adrenoceptors in this response was tested by exposure of the cells to a selective β_1 antagonist: CGP20712A (600 nM). When CGP20712A was present, 100 nM ISO had no significant effect on the amplitude of Ca²⁺ transients (*p* > 0.05, *n* = 4 batches of cells). It therefore appears that both α and β adrenoceptors are present and functional in our Gremlin 2/RA-treated hiPSC-derived atrial CMs, although we did not detect any changes in calcium removal back in the SR, which were expected (table 1).

3. Discussion

In the report presented here, we have developed a new protocol to generate functionally responsive atrial CMs from human iPSCs. The protocol involves temporal regulation of WNT and BMP signalling and the resultant cells structurally and functionally resemble atrial CMs in terms of atrial transcription programmes, electrophysiology and morphology.

The key findings in this report are: (i) development and validation of a new protocol consisting of treatment with Gremlin 2 and RA that permits differentiation of CMs with an atrial phenotype from human iPSCs; (ii) a substantial fraction of cells generated by this protocol showed a rod-shaped morphology with a single central nucleus similar to that observed in cells isolated from human atria; (iii) these myocytes demonstrated a distinctly atrial transcriptional programme; (iv) most isolated rod-shaped cells were electrically quiescent until stimulated to fire typical APs with an amplitude of 100 mV arising from a resting potential of approximately -70 mV; and (v) hiPSC-derived atrial CMs from this protocol responded to adrenergic stimuli by both α - or β -adrenoceptor agonists, and to cholinergic stimuli.

Development of our Gremlin 2 and RA combination treatment protocol for iPSC-AMs differentiation was based on previous observations showing that both of these agents can separately influence heart development (table 1). In zebrafish, Gremlin 2 was essential for the development of the heart [18]. Muller *et al.* [18] also showed that the ventricular and atrial CM specification was affected by the expression




Figure 3. Electrophysiological characterization. (a) AP traces recorded from quiescent (i,ii) and spontaneous beating (iii,iv) cardiomyocytes (CMs) in the experimental group with an atrial-type morphology. (b) Mean values shown as bar graphs for (i) resting membrane potential (RP), (ii) APA and (iii) APD at 90% repolarization (APD₉₀) and 50% repolarization (APD₅₀), measured from seven cells prepared using the experimental protocol. (c) Records from cells prepared using the control protocol and having a ventricular phenotype showing (i) a representative AP trace, (ii) mean APD₉₀ and APD₅₀, (iii) APA and (iv) RP measured from five control hiPSC-derived CMs. Data are presented as mean \pm s.e.m. (d) Currents induced by exposure to acetylcholine (ACh; 1 μ M) under whole-cell voltage clamp conditions for voltage steps in the range -110 to $+20$ mV recorded from an example cell in the experimental group with an atrial morphology are shown as red traces and labelled as $I_{K_{ACh-AM}}$. Corresponding traces from a control cell with a ventricular phenotype showing little or no current induced by ACh are shown in green and labelled as $I_{K_{ACh-VM}}$. The I–V curve showing a plot of current density against membrane potential (V) is shown in the right panel. The mean currents induced by ACh in cells prepared with the experimental protocol and having an atrial morphology are shown in red. The curve shows the expected inward rectification with a steep increase in current at negative potentials as compared with the flatter slope at depolarized potentials. There was little or no current in cells from the control group with a ventricular phenotype (green).




Figure 4. Changes in Ca²⁺ transient (CaT) amplitude in response to α - and β -adrenoceptor agonists in experimental group iPSC-CM cultures treated with Gremlin 2/RA. (a) CaTs (measured using Fluo-4 as the Ca²⁺ probe) in one representative experiment before and after 10 min of exposure to the α -adrenoceptor agonist, PE (10 μ M). In this and following panels, raw traces are shown in (i), averaged traces are shown in (ii), and graphs representing the mean increase in CaT amplitude are shown in (iii). Red traces in (i) and (ii) are in the presence of drugs while black traces are in their absence. A bar graph showing the mean increase in CaT in response to PE is shown in (iii). (b) CaTs in a representative experiment before and after 10 min of exposure to the β -adrenoceptor agonist isoproterenol (ISO; 100 nM). A bar graph showing the mean increase in CaT in response to isoproterenol is shown in (iii). (c) CaTs in response to PE (10 μ M) in the presence of the α -adrenergic antagonist (1 μ M prazosin). CaTs after 10 min exposure to PE were abolished by pretreatment with prazosin. Graph showing the mean changes in CaT amplitude in response to PE in the absence and presence of prazosin is shown in (iii). (d) CaTs in response to ISO (100 nM) in the presence of the β 1-adrenergic antagonist (300 nM GCP20712A). CaTs after 10 min exposure to ISO were abolished in iPSCs pre-treated with GCP20712A. Graph showing the mean changes in CaT amplitude in response to isoproterenol in the absence and presence of GCP20712A is shown in (iii). Four independent experiments were conducted for each drug combination shown in (a)–(d) (ii) and (iii). Data in (a)–(d) (iii) are shown as mean \pm s.e.m., * p < 0.05.

of Gremlin 2 because of its role in mediating phosphorylated SMAD1/5/8 and BMP signalling. Additional work [19] showed that Gremlin 2 enhanced cardiac differentiation and increased the atrial cell population in mouse ESC-derived CMs, as was evident from electrophysiological studies demonstrating a mixture of different AP shapes (ventricular, atrial and nodal) in untreated cells, while a dominant atrial-type AP was recorded from Gremlin 2-treated cells. Gene expression analysis also showed significantly higher expression of atrial-specific genes, *MYL7*, *GJA5*, *KCNJ5*, *CACNA1D1*, *SLN* and *NPPA* in the cells receiving Gremlin 2 treatment [15]. RA has separately been shown to influence heart development, by actions that are thought to involve modification of BMP signalling [51]. Currently, a range of RA-based protocols exist for iPSC/ESC differentiation into atrial CMs and similarly for Gremlin 2 [8–10,12,13,19,33,34,52,53] (table 1). While these differentiation protocols have shown success in establishing an atrial-like phenotype, they mostly produced immature cells, particularly in terms of electrophysiology and pharmacology. Thus, while the two agents have been shown separately to reliably induce an atrial-like phenotype, we sought to understand their combinatorial effect. It is interesting to speculate on the precise mechanism through which Gremlin 2 and RA synergize, as previously attempts with Noggin and RA have also produced atrial-specific CMs, albeit with a less robust atrial phenotype [54]. Both Noggin and Gremlin 2 both possess BMP antagonism [19]. However, Gremlin 2 activates *COUP-TFII* and *HEY1* in a JNK-sensitive manner not observed with Noggin signalling [19]. It is beyond the scope of this study, but it will be interesting to further characterize the putative role of JNK signalling in atrial differentiation. The combined use of Gremlin 2 and RA introduced in our experiments described above substantially increased the effectiveness of the new protocol in directing iPSC development towards a more mature atrial phenotype and excitingly across several structural and functional domains of maturity.

An important feature of the cardiac cells produced by the novel methods described here is a morphology that resembles the adult atrial phenotype. The cells had a single nucleus and approximately 40% showed an elongated ‘rod’ shape that is characteristic of adult myocytes. This was particularly evident in isolated cells that had been dispersed from cell cultures (figure 1c). Immunohistochemistry demonstrated that the expression of atrial-specific proteins, particularly *COUP-TFII* and *NPPA*, was greater in cultures from the Gremlin 2/RA-treated experimental group than in cultures from the commercially derived group (with 78% CMs showing *COUP-TFII* expression in the treated experimental group as compared with 9% in the control group).

A more extensive transcriptome analysis by single-cell RNA-sequencing on over 300 cells from each group provided further evidence that Gremlin 2/RA treatment elicited a more atrial transcriptional programme than in the control group: atrial genes showing enhanced expression included: *MYL7*, *HEY1*, *HOXA3*, *SLN*, *MYH6*, *KCNH2*, *GATA4* and *NPPA*; whereas the control group had a predominately more ventricular transcriptomic signature, with greater expression of ventricular transcription factors such as *IRX5* and *IRX4*. We used the unbiased nature of scRNAseq to cross-validate our protein-level expression of atrial markers following Gremlin 2/RA treatment (figure 1). We observed the Gremlin 2/RA-treatment produced an increased percentage of atrial CMs

from 16% in the control group to 71% in the experimental group. Particular genes that were upregulated were those that are important for atrial cell function, including ion channels (e.g. *KCNA5*, *KCNJ2*, *KCNJ3* and *KCNH2*) and calcium-handling proteins (e.g. *RYR2*, *CACNA1H*, *CACNA1G* and *SLC8A1*). It is interesting to note that our scRNAseq analysis suggests that despite robust expression of *NR2F2* in the control group to a somewhat comparable degree as the experimental group (figure 2d), this does not appear to be coupled to an increase in the protein levels of its gene product *COUP-TFII* (figure 1b,d), nor to an atrial transcriptional programme (figure 2). This highlights the opportunity of *in vitro* differentiation protocols to study normal developmental signalling and mandates further study to ascertain the epigenetic regulation of *NR2F2*.

In view of the above messenger RNA (mRNA) expression of genes coding for atrial ion channels, it is perhaps unsurprising that electrophysiological recording provided important additional information supporting the effectiveness of the new Gremlin 2/RA treatment in directing iPSC development towards the adult atrial phenotype. When single cells were isolated from the cultures in which they were grown, they were generally electrically quiescent, and brief current stimuli were needed to initiate APs, to the authors’ knowledge this has not been previously reported. The resting membrane potential approached -70 mV, and the amplitude of APs was approximately 100 mV consistent with an overshoot of approximately 30 mV. The shape and duration of APs was also broadly consistent with the adult atrial phenotype. Similarly, the amplitude of APs using the improved protocol with a combination of Gremlin 2 and RA is also larger than in previous reports using either as a differential factor in isolation [9,33,52,54]. In particular, it is important to note the improved activity and larger current we recorded from the preferentially atrial current $I_{K_{ACh}}$ compared to previous RA-only protocols [8,13], with ours much closer to that seen in adult human atrial CMs [55]. Additionally, our robust $I_{K_{ACh}}$ signal was concomitant with more clear mature sarcomeric subcellular structure, which was less obvious in other protocols with robust $I_{K_{ACh}}$ signal [8]. We highlight $I_{K_{ACh}}$ for particular note given the major importance of this current in atrial repolarization and membrane stability and its implication in AF [56,57] which makes a robust $I_{K_{ACh}}$ current probably a necessity for meaningful modelling of AF, drug development and translational work using hiPSC-derived atrial CMs. Although the above characteristics show close similarities to those of adult CMs, there is always the prospect of making these similarities closer still and a recent review [58] discusses variability and disparity of hiPSC characteristics across different ‘-omic’ levels, while recognizing the importance of these approaches in characterizing PSC-derived CMs. Further study interrogating more detailed electrophysiological behaviour of our iPSC-AMs will help elucidate the complexities. Nevertheless all the features discussed above make iPSC-AMs derived using our new Gremlin 2/RA protocol suitable for the testing of beneficial and harmful effects of drugs on human cardiac atrial muscle.

We also sought to investigate the dominant electrophysiological properties of the two cell culture conditions (experimental against control) beyond individual currents. While it would have been interesting to see the difference between our hiPSC-derived atrial CMs, and atrial CMs from the control group treated with commercial reagents

only, we compared the dominant and modal phenotype in each condition. This ventricular-like and atrial-like behaviour from the control and experimental groups, respectively, was representative of all of the cells we assayed in either group via patch clamp. The modal cell in a given culture will influence the pre-dominant electrophysiological phenotype, and thus our results give an unbiased consideration of the two groups, without any bias introduced through positive or negative selection of the cells for comparison.

Another important characteristic of the iPSC-AMs produced by this protocol that provides a useful experimental model for studying human cardiac muscle function is the ability to respond to selective neurohormonal signalling agonists: PE, ISO and ACh. The observation that the adrenergic effects could be blocked by the appropriate antagonists provided further support for the expression and functional intracellular coupling of both α and β adrenoceptors in the cells prepared by the methods described here (figure 4). The changes in the Ca^{2+} transient amplitudes that were observed in response to both α and β adrenoceptor stimulation are consistent with the presence and activity of the intracellular cAMP signalling modules downstream of adrenoceptor stimulation. We did not detect a clear positive lusitropic effect from β adrenoceptor stimulation, but this point will be the subject of more detailed future studies. However, to the knowledge of the authors, this is the first iPSC-derived atrial CM differentiation protocol to produce a robust response to adrenergic stimuli without further maturation protocols [8–15]. Furthermore, our I_{KACH} current density in response to 1 μM ACh was equivalent to native human mature atrial CMs. The ability of our iPSC-AMs to respond to both adrenergic and cholinergic activators provides a useful model for studying the interaction of these key cardiac modulators in atrial disease.

In summary, the key features of the cells that mark out advances of the approach presented are rod-shaped morphology in a large fraction of the cells (approximately 40%); expression of atrial-specific transcripts; electrophysiological characteristics, closely resembling the adult atrial phenotype; and ability to respond to adrenoceptor and cholinoreceptor stimulation. It seems likely that these human cells, with characteristics closely resembling those of the adult atrial phenotype, will provide an important resource for drug testing (particularly drugs to treat AF) and for the investigation of cell signalling mechanisms.

4. Material and methods

(a) Induced pluripotent stem cell culturing, differentiation and characterisations

The iPSC lines used for the CM differentiation were purchased from Gibco® Life Technology, Carlsbad, USA or developed in the laboratory. Cord blood-derived CD34⁺ progenitor cells were reprogrammed into iPSCs by using a three-plasmid and seven-factor episomal system (OCT4, Sox2, Myc, Klf4, Nanog, SV40LT and Lin28 antigen). iPSC lines were fully characterized by (i) immunostaining, (ii) qPCR, (iii) tri-lineage differentiation, (iv) teratoma assay and (v) karyotyping as described in Appendix.

iPSC line was cultured on a Matrigel-coated six-well culture plate with mTeSR™1 medium (STEMCELL™ Technologies), human iPSCs were maintained undifferentiated with daily medium change as the protocol described in detail in Appendix.

(b) Cardiomyocyte isolation and immunofluorescent characterization

CM aggregates were dissociated by using Accutase™ (STEMCELL™ Technologies). Following a Dulbecco's phosphate buffered saline wash, Accutase™ was added to the CMs for 8 min at 37°C. After the addition of 2–3 volume of fresh cardiomyocyte maintenance medium (CMM) to terminate the reaction of Accutase™, the cells were firstly physically detached and collected by 1000 μl pipette. Subsequently, dissociated CMs were transferred and seeded to a 1:30 Matrigel-coated polymer-made coverslip. They were cultured with CMM and 10 μm Y-27 683 for at least two days prior to immunofluorescent examination. The dissociated iPSC-derived CMs cultured on the polymer-made coverslips (ibidi Technologies) were washed with PBS and fixed with 4% paraformaldehyde [17] at room temperature for 20 min and then went through various steps of staining as described in Appendix in detail. The immunocytochemistry images were analysed by IMAGEJ.

(c) Single-cell RNA-sequencing and RT-qPCR

Human iPSC-derived CMs were collected as the protocols described in Appendix and were fixed by chilled methanol and stored on ice for 15 min for fixation prior to -80°C storage. The fixed cells were rehydrated using a FACS Aria II or FACSJazz (BD Biosciences). Single cells (based on DAPI exclusion and forward/side scatter properties) were sorted into 384-well hard-shell plates (Biorad) with 5 μl of vapour-lock (QIAGEN) containing 100–200 nl of RT primers, dNTPs and synthetic mRNA Spike-Ins and immediately spun down and frozen to -80°C . Sort-sequencing was used for single-cell RNAseq. In brief, CMs were lysed by 5 min at 65°C, when RT and second strand mixes were dispersed with the Nanodrop II liquid handling platform (GC biotech). The aqueous phase was split from the oil phase after pooling all CMs in one library, followed by IVT transcription. For library preparation, CEL-Seq2 protocol was applied. Primers were composed of a 4 bp random molecular barcode, 24 bp polyT stretch, a T7 promoter, a cell-specific 8 bp barcode and the 5' Illumina TruSeq small RNA kit adaptor. Single-cell mRNA was subsequently reverse transcribed, converted to double-stranded cDNA, assembled and *in vitro* transcribed for linear as required for the CEL-Seq 2 protocol [59]. Illumina-sequencing libraries were then made with the TruSeq small RNA primers (Illumina) and sequenced paired-end at 75 bp read length the Illumina NextSeq. Read alignment was performed. Subsequently, candidate cells and genes were analysed in the R environment. Cells were filtered using a criteria in which transcript number > 12 000 and gene were filtered > 5 transcript in more than five cells. Differential gene expression analysis was performed via RaceID (v0.1.5) [60]. Violin plots were generated by using the R package ggplot2 (v3.2.1) [61] and heatmaps were made by using R package ComplexHeatmap (v2.1.2) [62]. GO enrichment analysis was performed and visualized using CLUSTERPROFILER [63].

For RT-qPCR, various gene expressions were analysed to identify the derived cells as CMs, and to subsequently testify the subtype specificity of the derived CMs. Quantitative PCR analysis was conducted for atrial-specific genes (*NPPA*, *MYL7*), inward rectifier potassium channel coding genes (*KCNJ2*), other potassium channel-encoding genes (*KCNA5*) and ventricular-specific genes (*MYL2*, *IRX4*). All the TaqMan® Gene Expression Assays were pre-designed by Applied Biosystems by Thermo Fisher Scientific. qPCR was performed with LightCycler®480 (Roche) using TaqMan® Gene Expression Master Mix (Applied Biosystems by Thermo Fisher Scientific) under the instructions from the manufacturer.

(d) Electrophysiological studies and Ca^{2+} imaging

AP recording was recorded by patch clamp under a whole-cell configuration using Axon 700B amplifier system (Molecular Devices, USA). For the records of APs, the pipette solution contained (in mmol l^{-1}): K-aspartate 110, KCl 10, NaCl 5, MgCl_2 5.2, HEPES 5, K_2ATP 5 and pH 7.2 with KOH. For the measurements of I_{KACH} , the cells were voltage clamped and the pipette solution contained (in mmol l^{-1}): K-aspartate 136, KCl 5.4, NaCl 5, MgCl_2 1, HEPES 1, EGTA 5, Mg-ATP 5, phosphocreatine 5, pH 7.2 with KOH. The bath solution consisted of (in mmol l^{-1}) NaCl 136, KCl 5.4, MgCl_2 1.0, CaCl_2 1.8, NaH_2PO_4 0.33, HEPES 5, Glucose 10, pH 7.4 with NaOH. No compensation was applied for changes in junction potential during whole-cell recording, but correction with aspartate as the major anion would have resulted in a small shift in recorded potential in the hyperpolarizing direction [44]. In experiments where I_{KACH} was to be measured, cells were voltage clamped at a holding potential of -40 mV and step depolarizations were applied in the range -120 mV to $+20$ mV in increments of 10 mV. ACh was applied at a concentration of $1 \mu\text{M}$ and currents in the absence of ACh were subtracted from currents in the presence of ACh to give I_{KACH} .

Optical mapping experiments were carried out after the cells started to contract. The responsiveness of the derived CMs in the experimental group to β - and α -adrenergic receptor agonists and antagonists was measured. Intracellular calcium transients were analysed using a 128×128 EMCCD camera (Photometrics, Tucson, USA). The derived CMs were pre-loaded with $1 \mu\text{M}$ Fluo4 (Molecular Probes by Life Technologies) dissolved in dimethyl sulfoxide for 15 min at 37°C in CMM. Calcium transients of the derived CMs were first recorded without the addition of the drugs as control. Recordings were then taken at 0 min, 5 min, 10 min and 15 min after 100 nM ISO treatment. Using the same method, the responsiveness of the derived CMs in the experimental group to $10 \mu\text{M}$ PE treatment was tested. In adrenergic receptor antagonist tests, the cells were pre-treated with 600 nM CGP20712A (CGP) (Sigma) dissolved in Fluo4-loading solution prior to 100 nM ISO treatment. Recordings were taken in the same way as described above. Similarly, the cells were pre-treated with $1 \mu\text{M}$ prazosin dissolved in Fluo4-loading solution before a treatment of $10 \mu\text{M}$ PE. Metamorph was used to take the recordings, and 4000 or 8000 frames were taken for each recording, with a frame rate of 100 Hz (for 4000 frames) or 333.33 Hz (for 8000 frames). Regions of interest were selected using IMAGEJ. Raw traces were analysed and baseline corrections were conducted

using Clampfit. Calcium transient amplitude change was calculated based on averaged trace. Electrophysiological analysis was performed, in part, using ELECTROMAP [64] on MATLAB. To calculate beat-to-beat CaT50 , the mean signal was segmented into individual beats. Representative regions were defined as two 16×16 pixel regions.

Data accessibility. All data are contained within the manuscript. Reasonable requests for raw data and analysis scripts should be made to the corresponding author.

Authors' contributions. D.A.T.: conceptualization, data curation, formal analysis, funding acquisition, investigation, methodology, project administration, resources, supervision, validation, visualization, writing—original draft, writing—review and editing; F.S.A.: conceptualization, data curation, formal analysis, investigation, methodology, writing—original draft, writing—review and editing; .Y.J.: data curation, formal analysis, investigation, methodology, writing—original draft, writing—review and editing; A.G.R.: data curation, formal analysis, investigation, methodology, writing—original draft, writing—review and editing; Y.Z.: data curation, formal analysis, investigation, methodology, supervision, writing—original draft, writing—review and editing; M.Y.: data curation, formal analysis, investigation, writing—review and editing; X.F.: data curation, formal analysis, investigation, writing—review and editing; R.Z.: data curation, formal analysis, investigation, writing—review and editing; R.M.: data curation, formal analysis, investigation, writing—review and editing; C.O.: data curation, formal analysis, investigation, writing—review and editing; A.M.: writing—original draft, writing—review and editing; W.H.: data curation, formal analysis, investigation, writing—review and editing; Y.A.: data curation, formal analysis, investigation, writing—review and editing; M.Y.: data curation, investigation, writing—review and editing; D.P.: data curation, writing—review and editing; Y.Z.: data curation, formal analysis, investigation, methodology, supervision, writing—review and editing; X.T.: data curation, formal analysis, funding acquisition, project administration, supervision, writing—original draft, writing—review and editing; M.L.: conceptualization, data curation, formal analysis, funding acquisition, investigation, methodology, project administration, supervision, writing—original draft, writing—review and editing.

All authors gave final approval for publication and agreed to be held accountable for the work performed therein.

Conflicts of interest declaration. F.S.A. now works for Cure8bio and holds shares in Cambrian Biopharma, Inc. and Vita Therapeutics, Inc.

Funding. Our work is supported by the Magdi Yacoub Foundation (F.S.A. and D.A.T.) and British Heart Foundation (BHF) (BHF Centre for Research Excellence (CRE) at Oxford, PG/14/80/31106, PG/16/67/32340, PG/12/21/29473 and FS/PhD/20/29053).

References

- Wann LS *et al.* 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation* **123**, 104–123. (doi:10.1161/CIR.0b013e3181fa3cf4)
- de Vos CB *et al.* 2010 Progression from paroxysmal to persistent atrial fibrillation: clinical correlates and prognosis. *J. Am. Coll. Cardiol.* **55**, 725–731. (doi:10.1016/j.jacc.2009.11.040)
- Musunuru K *et al.* 2018 Induced pluripotent stem cells for cardiovascular disease modeling and precision medicine: a scientific statement from the American Heart Association. *Circu. Genomic Precision Med.* **11**, e000043.
- Yazawa M, Hsueh B, Xia X, Pasca AM, Bernstein JA, Hallmayer J, Dolmetsch RE. 2011 Using iPSC cells to investigate cardiac phenotypes in patients with Timothy Syndrome. *Nature* **471**, 230–234. (doi:10.1038/nature09855)
- Itzhaki I *et al.* 2011 Modelling the long QT syndrome with induced pluripotent stem cells. *Nature* **471**, 225–229. (doi:10.1038/nature09747)
- Lundy SD, Zhu WZ, Regnier M, Laflamme MA. 2013 Structural and functional maturation of cardiomyocytes derived from human pluripotent stem cells. *Stem Cells Dev.* **22**, 1991–2002. (doi:10.1089/scd.2012.0490)
- Yoshida S, Miyagawa S, Fukushima S, Kawamura T, Kashiya N, Ohashi F, Toyofuku T, Toda K, Sawa Y. 2018 Maturation of human induced pluripotent stem cell-derived cardiomyocytes by soluble factors from human mesenchymal stem cells. *Mol. Ther.* **26**, 2681–2695. (doi:10.1016/j.yth.2018.08.012)
- Devalla HD *et al.* 2015 Atrial-like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial-selective pharmacology. *EMBO Mol. Med.* **7**, 394–410. (doi:10.15252/emmm.201404757)
- Lee JH, Protze SI, Laksman Z, Backx PH, Keller GM. 2017 Human pluripotent stem cell-derived atrial and ventricular cardiomyocytes develop from distinct mesoderm populations. *Cell Stem Cell.* **21**, 179–194. (doi:10.1016/j.stem.2017.07.003)
- Laksman Z *et al.* 2017 Modeling atrial fibrillation using human embryonic stem cell-derived atrial tissue. *Sci. Rep.* **7**, 5268. (doi:10.1038/s41598-017-05652-y)
- Argenziano M *et al.* 2018 Electrophysiologic characterization of calcium handling in human induced pluripotent stem cell-derived atrial

- cardiomyocytes. *Stem Cell Rep.* **10**, 1867–1878. (doi:10.1016/j.stemcr.2018.04.005)
12. Cyganek L *et al.* 2018 Deep phenotyping of human induced pluripotent stem cell-derived atrial and ventricular cardiomyocytes. *JCI Insight* **3**, e99941. (doi:10.1172/jci.insight.99941)
 13. Lemme M *et al.* 2018 Atrial-like engineered heart tissue: an *in vitro* model of the human atrium. *Stem Cell Rep.* **11**, 1378–1390. (doi:10.1016/j.stemcr.2018.10.008)
 14. Shafaattalab S *et al.* 2019 Ibrutinib displays atrial-specific toxicity in human stem cell-derived cardiomyocytes. *Stem Cell Rep.* **12**, 996–1006. (doi:10.1016/j.stemcr.2019.03.011)
 15. Zhao Y *et al.* 2019 A platform for generation of chamber-specific cardiac tissues and disease modeling. *Cell* **176**, 913–927. (doi:10.1016/j.cell.2018.11.042)
 16. Chanda B, Ditadi A, Iscove NN, Keller G. 2013 Retinoic acid signaling is essential for embryonic hematopoietic stem cell development. *Cell* **155**, 215–227. (doi:10.1016/j.cell.2013.08.055)
 17. Kawagishi-Hotta M *et al.* 2019 Increase of Gremlin 2 with age in human adipose-derived stromal/stem cells and its inhibitory effect on adipogenesis. *Regen. Ther.* **11**, 324–330. (doi:10.1016/j.reth.2019.09.002)
 18. Müller II *et al.* 2013 Functional modeling in zebrafish demonstrates that the atrial-fibrillation-associated gene GREM2 regulates cardiac laterality, cardiomyocyte differentiation and atrial rhythm. *Dis Model Mech.* **6**, 332–341.
 19. Tanwar V *et al.* 2014 Gremlin 2 promotes differentiation of embryonic stem cells to atrial fate by activation of the JNK signaling pathway. *Stem Cells* **32**, 1774–1788. (doi:10.1002/stem.1703)
 20. Bénardeau A, Hatem SN, Rücker-Martin C, Tessier S, Dinanian S, Samuel JL, Coraboeuf E, Mercadier JJ. 1997 Primary culture of human atrial myocytes is associated with the appearance of structural and functional characteristics of immature myocardium. *J. Mol. Cell. Cardiol.* **29**, 1307–1320. (doi:10.1006/jmcc.1996.0366)
 21. Amos GJ, Wettwer E, Metzger F, Li Q, Himmel HM, Ravens U. 1996 Differences between outward currents of human atrial and subepicardial ventricular myocytes. *J. Physiol.* **491**, 31–50. (doi:10.1113/jphysiol.1996.sp021194)
 22. Dobrev D, Graf E, Wettwer E, Himmel HM, Hála O, Doerfel C, Christ T, Schuiler S, Ravens U. 2001 Molecular basis of downregulation of G-protein coupled inward rectifying K⁺ current (I_{K,ACh}) in chronic human atrial fibrillation. *Circulation* **104**, 2551–2557. (doi:10.1161/hc4601.099466)
 23. Wang Y, Xu H, Kumar R, Tipparaju SM, Wagner MB, Joyner RW. 2003 Differences in transient outward current properties between neonatal and adult human atrial myocytes. *J. Mol. Cell. Cardiol.* **35**, 1083–1092. (doi:10.1016/S0022-2828(03)00200-1)
 24. Pandit SV. 2018 31 - Ionic mechanisms of atrial action potentials. In *Cardiac electrophysiology: from cell to bedside*, 7th edn (eds DP Zipes, J Jalife, WG Stevenson), pp. 293–303. Amsterdam, The Netherlands: Elsevier.
 25. Jeevaratnam K, Chadda KR, Huang CLH, Camm AJ. 2018 Cardiac potassium channels: physiological insights for targeted therapy. *J. Cardiovasc. Pharmacol. Ther.* **23**, 119–129. (doi:10.1177/1074248417729880)
 26. Bolger AP, Sharma R, Li W, Leenarts M, Kalra PR, Kemp M, Coats AJS, Anker SD, Gatzoulis MA. 2002 Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. *Circulation* **106**, 92–99. (doi:10.1161/01.CIR.0000020009.30736.3F)
 27. Bosch RF, Zeng X, Grammer JB, Popovic K, Mewis C, Kühlkamp V. 1999 Ionic mechanisms of electrical remodeling in human atrial fibrillation. *Cardiovasc. Res.* **44**, 121–131. (doi:10.1016/S0008-6363(99)00178-9)
 28. Cui Y *et al.* 2019 Single-cell transcriptome analysis maps the developmental track of the human heart. *Cell Rep.* **26**, 1934–1950. (doi:10.1016/j.celrep.2019.01.079)
 29. Li G, Tian L, Goodyer W, Kort EJ, Buikema JW, Xu A, Wu J, Jovinge S, Wu SM. 2019 Single cell expression analysis reveals anatomical and cell cycle-dependent transcriptional shifts during heart development. *Development* **146**, dev173476. (doi:10.1242/dev.173476)
 30. Grandi E, Pandit SV, Voigt N, Workman AJ, Dobrev D, Jalife J, Bers DM. 2011 Human atrial action potential and Ca²⁺ model: sinus rhythm and chronic atrial fibrillation. *Circ. Res.* **109**, 1055–1066. (doi:10.1161/CIRCRESAHA.111.253955)
 31. Li J *et al.* 2022 Molecular and electrophysiological evaluation of human cardiomyocyte subtypes to facilitate generation of composite cardiac models. *J. Tissue Eng.* **13**, 20417314221127908.
 32. Pei F, Jiang J, Bai S, Cao H, Tian L, Zhao Y, Yang C, Dong H, Ma Y. 2017 Chemical-defined and albumin-free generation of human atrial and ventricular myocytes from human pluripotent stem cells. *Stem Cell Res.* **19**, 94–103. (doi:10.1016/j.scr.2017.01.006)
 33. Goldfracht I, Protze S, Shiti A, Setter N, Gruber A, Shaheen N, Nartiss Y, Keller G, Gepstein L. 2020 Generating ring-shaped engineered heart tissues from ventricular and atrial human pluripotent stem cell-derived cardiomyocytes. *Nat. Commun.* **11**, 75. (doi:10.1038/s41467-019-13868-x)
 34. Bylund JB, Hatzopoulos AK. 2016 Differentiation of atrial cardiomyocytes from pluripotent stem cells using the BMP antagonist Grem2. *J. Vis. Exp.*
 35. Smyrnias I, Mair W, Harzheim D, Walker SA, Roderick HL, Bootman MD. 2010 Comparison of the T-tubule system in adult rat ventricular and atrial myocytes, and its role in excitation-contraction coupling and inotropic stimulation. *Cell Calcium* **47**, 210–223. (doi:10.1016/j.ceca.2009.10.001)
 36. Wu SP *et al.* 2013 Atrial identity is determined by a COUP-TFII regulatory network. *Dev. Cell* **25**, 417–426. (doi:10.1016/j.devcel.2013.04.017)
 37. Feng J, Wang Z, Li GR, Nattel S. 1997 Effects of class III antiarrhythmic drugs on transient outward and ultra-rapid delayed rectifier currents in human atrial myocytes. *J. Pharmacol. Exp. Therap.* **281**, 384–392.
 38. Costantini DL *et al.* 2005 The homeodomain transcription factor Irx5 establishes the mouse cardiac ventricular repolarization gradient. *Cell* **123**, 347–358. (doi:10.1016/j.cell.2005.08.004)
 39. Nygren A, Fiset C, Firek L, Clark JW, Lindblad DS, Clark RB, Giles WR. 1998 Mathematical model of an adult human atrial cell. *Circ. Res.* **82**, 63–81. (doi:10.1161/01.RES.82.1.63)
 40. Goversen B, van der Heyden MAG, van Veen TAB, de Boer TP. 2018 The immature electrophysiological phenotype of iPSC-CMs still hampers *in vitro* drug screening: special focus on IK1. *Pharmacol. Ther.* **183**, 127–136. (doi:10.1016/j.pharmthera.2017.10.001)
 41. Giannini G, Conti A, Mammarella S, Scrobogna M, Sorrentino V. 1995 The ryanodine receptor/calcium channel genes are widely and differentially expressed in murine brain and peripheral tissues. *J. Cell Biol.* **128**, 893–904. (doi:10.1083/jcb.128.5.893)
 42. Iacobas S, Amuzescu B, Iacobas DA. 2021 Transcriptomic uniqueness and commonality of the ion channels and transporters in the four heart chambers. *Sci. Rep.* **11**, 2743. (doi:10.1038/s41598-021-82383-1)
 43. Niwa N *et al.* 2004 Cav3.2 subunit underlies the functional T-type Ca²⁺ channel in murine hearts during the embryonic period. *Am. J. Physiol. Heart Circ. Physiol.* **286**, H2257–H2263. (doi:10.1152/ajpheart.01043.2003)
 44. Rog-Zielinska EA *et al.* 2015 Glucocorticoids promote structural and functional maturation of foetal cardiomyocytes: a role for PGC-1 α . *Cell Death Differ.* **22**, 1106–1116. (doi:10.1038/cdd.2014.181)
 45. Nelson DO *et al.* 2016 Irx4 marks a multipotent, ventricular-specific progenitor cell. *Stem Cells* **34**, 2875–2888. (doi:10.1002/stem.2486)
 46. Giles WR, Imaizumi Y. 1988 Comparison of potassium currents in rabbit atrial and ventricular cells. *J. Physiol.* **405**, 123–145. (doi:10.1113/jphysiol.1988.sp017325)
 47. Sakmann B, Noma A, Trautwein W. 1983 Acetylcholine activation of single muscarinic K⁺ channels in isolated pacemaker cells of the mammalian heart. *Nature* **303**, 250–253. (doi:10.1038/303250a0)
 48. Krapivinsky G, Gordon EA, Wickman K, Velimirović B, Krapivinsky L, Clapham DE. 1995 The G-protein-gated atrial K⁺ channel IK_{ACh} is a heteromultimer of two inwardly rectifying K⁺-channel proteins. *Nature* **374**, 135–141. (doi:10.1038/374135a0)
 49. Ertl R, Jahnel U, Nawrath H, Carmeliet E, Vereecke J. 1991 Differential electrophysiologic and inotropic effects of phenylephrine in atrial and ventricular heart muscle preparations from rats. *Naunyn Schmiedeberg's Arch. Pharmacol.* **344**, 574–581. (doi:10.1007/BF00170655)
 50. Brodde OE, Michel MC. 1999 Adrenergic and muscarinic receptors in the human heart. *Pharmacol. Rev.* **51**, 651–690.
 51. Kikuchi K, Holdway JE, Major RJ, Blum N, Dahn RD, Begemann G, Poss K. 2011 Retinoic acid production by endocardium and epicardium is an injury response essential for zebrafish heart regeneration.

- Dev. Cell* **20**, 397–404. (doi:10.1016/j.devcel.2011.01.010)
52. Liu F *et al.* 2022 The biphasic effect of retinoic acid signaling pathway on the biased differentiation of atrial-like and sinoatrial node-like cells from hiPSC. *Int. J. Stem Cells* **15**, 247–257.
 53. Gunawan MG, Sangha SS, Shafaattalab S, Lin E, Heims-Waldron DA, Bezzerides VJ, Laksman Z, Tibbits GF. 2021 Drug screening platform using human induced pluripotent stem cell-derived atrial cardiomyocytes and optical mapping. *Stem Cells Transl. Med.* **10**, 68–82. (doi:10.1002/sctm.19-0440)
 54. Zhang Q *et al.* 2011 Direct differentiation of atrial and ventricular myocytes from human embryonic stem cells by alternating retinoid signals. *Cell Res.* **21**, 579–587. (doi:10.1038/cr.2010.163)
 55. Koumi S, Arentzen CE, Backer CL, Wasserstrom JA. 1994 Alterations in muscarinic K⁺ channel response to acetylcholine and to G protein-mediated activation in atrial myocytes isolated from failing human hearts. *Circulation* **90**, 2213–2224.
 56. Skarsfeldt MA, Bomholtz SH, Lundegaard PR, Lopez-Izquierdo A, Tristani-Firouzi M, Bentzen BH. 2018 Atrium-specific ion channels in the zebrafish—a role of IKACH in atrial repolarization. *Acta Physiol.* **223**, e13049.
 57. Schmitt N, Grunnet M, Olesen SP. 2014 Cardiac potassium channel subtypes: new roles in repolarization and arrhythmia. *Physiol. Rev.* **94**, 609–653.
 58. Biendarra-Tiegs SM, Li X, Ye D, Brandt EB, Ackerman MJ, Nelson TJ. 2019 Single-cell RNA-sequencing and optical electrophysiology of human induced pluripotent stem cell-derived cardiomyocytes reveal discordance between cardiac subtype-associated gene expression patterns and electrophysiological phenotypes. *Stem Cells Dev.* **28**, 659–673.
 59. Hashimshony T *et al.* 2016 CEL-Seq2: sensitive highly-multiplexed single-cell RNA-Seq. *Genome Biol.* **17**, 1–7.
 60. Herman JS, Sagar GD. 2018 FateID infers cell fate bias in multipotent progenitors from single-cell RNA-seq data. *Nat. Methods* **15**, 379–386.
 61. Villanueva RAM, Chen ZJ. 2019 ggplot2: elegant graphics for data analysis, 2nd ed. *Measurement: Interdisc. Res. Perspect.* **17**, 160–167.
 62. Gu Z, Eils R, Schlesner M. 2016 Complex heatmaps reveal patterns and correlations in multidimensional genomic data. *Bioinformatics* **32**, 2847–2849.
 63. Love MI, Huber W, Anders S. 2014 Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550.
 64. O'Shea C *et al.* 2019 ElectroMap: high-throughput open-source software for analysis and mapping of cardiac electrophysiology. *Sci. Rep.* **9**, 1389.